Although there are no approved drugs that specifically inhibit SRPK1/2, the anaplastic lymphoma kinase (ALK) inhibitor Alectinib, which is used clinically to treat nonsmall-cell lung cancer, also leads to inhibition of SRPK1/2 (17). Here, ALK is linked to lung cancer.